BIODESIX, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
BIODESIX, INC. (BDSX) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$15.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-05
- BIODESIX, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$7.27M.
- BIODESIX, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$7.79M.
- BIODESIX, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$3.98M.
- BIODESIX, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$8.72M.
- BIODESIX, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$35.27M.
- BIODESIX, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$42.93M.
- BIODESIX, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$52.15M.
- BIODESIX, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$65.45M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$15.07M 10-Q · filed 2026-08-05 | -$19.05M derived: sum of 3 quarters · filed 2026-08-05 | -$27.76M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$7.79M 10-Q · filed 2026-05-04 | -$11.77M derived: sum of 2 quarters · filed 2026-05-04 | -$20.49M derived: sum of 3 quarters · filed 2026-05-04 | -$31.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$3.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$12.70M derived: sum of 2 quarters · filed 2026-02-26 | -$24.16M derived: sum of 3 quarters · filed 2026-08-05 | -$35.27M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$8.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$20.18M derived: sum of 2 quarters · filed 2026-08-05 | -$31.29M 10-Q · filed 2025-11-03 | -$39.54M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$11.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$22.57M 10-Q · filed 2026-08-05 | -$30.82M derived: sum of 3 quarters · filed 2026-08-05 | -$41.08M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$11.10M 10-Q · filed 2026-05-04 | -$19.35M derived: sum of 2 quarters · filed 2026-05-04 | -$29.61M derived: sum of 3 quarters · filed 2026-05-04 | -$40.42M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$8.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$18.51M derived: sum of 2 quarters · filed 2026-02-26 | -$29.32M derived: sum of 3 quarters · filed 2026-02-26 | -$42.93M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$10.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$21.07M derived: sum of 2 quarters · filed 2025-11-03 | -$34.68M 10-Q · filed 2025-11-03 | -$43.82M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | -$10.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$24.42M 10-Q · filed 2025-08-07 | -$33.56M derived: sum of 3 quarters · filed 2025-08-07 | -$44.51M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$13.61M 10-Q · filed 2025-05-13 | -$22.75M derived: sum of 2 quarters · filed 2025-05-13 | -$33.70M derived: sum of 3 quarters · filed 2025-05-13 | -$47.06M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$9.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$20.09M derived: sum of 2 quarters · filed 2025-03-03 | -$33.44M derived: sum of 3 quarters · filed 2025-03-03 | -$52.15M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$10.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | -$24.30M derived: sum of 2 quarters · filed 2024-11-01 | -$43.01M 10-Q · filed 2024-11-01 | -$63.34M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | -$13.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$32.06M 10-Q · filed 2024-08-07 | -$52.40M derived: sum of 3 quarters · filed 2024-08-07 | -$66.09M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$18.70M 10-Q · filed 2024-05-08 | -$39.04M derived: sum of 2 quarters · filed 2024-05-08 | -$52.74M derived: sum of 3 quarters · filed 2024-05-08 | -$68.56M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$20.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$34.04M derived: sum of 2 quarters · filed 2024-03-01 | -$49.86M derived: sum of 3 quarters · filed 2024-03-01 | -$65.45M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$13.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$29.52M derived: sum of 2 quarters · filed 2023-11-07 | -$45.11M 10-Q · filed 2023-11-07 | -$58.39M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$15.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$31.41M 10-Q · filed 2023-08-07 | -$44.69M derived: sum of 3 quarters · filed 2023-08-07 | -$56.21M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$15.59M 10-Q · filed 2023-05-11 | -$28.87M derived: sum of 2 quarters · filed 2023-05-11 | -$40.38M derived: sum of 3 quarters · filed 2023-05-11 | -$51.78M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$13.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$24.80M derived: sum of 2 quarters · filed 2023-03-06 | -$36.20M derived: sum of 3 quarters · filed 2023-03-06 | -$43.16M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$11.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$22.92M derived: sum of 2 quarters · filed 2022-11-03 | -$29.88M 10-Q · filed 2022-11-03 | -$34.41M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$11.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$18.36M 10-Q · filed 2022-08-04 | -$22.90M derived: sum of 3 quarters · filed 2022-08-04 | -$31.74M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$6.96M 10-Q · filed 2022-05-11 | -$11.49M derived: sum of 2 quarters · filed 2022-05-11 | -$20.34M derived: sum of 3 quarters · filed 2022-05-11 | -$28.61M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | -$4.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$13.38M derived: sum of 2 quarters · filed 2022-03-14 | -$21.64M derived: sum of 3 quarters · filed 2022-03-14 | -$31.35M 10-K · filed 2022-03-14 |
| 2020-09-30 | -$8.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$17.11M derived: sum of 2 quarters · filed 2021-11-15 | -$26.82M 10-Q · filed 2021-11-15 | -$33.34M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | -$8.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$17.97M 10-Q · filed 2021-08-10 | -$24.50M derived: sum of 3 quarters · filed 2021-08-10 | |
| 2020-03-31 | -$9.71M 10-Q · filed 2021-05-11 | -$16.23M derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | -$6.53M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$30.73M 10-K · filed 2021-03-16 | ||
| 2019-09-30 | -$24.20M 10-Q · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |